AB Science Developing Two Main Compounds

Biopharmaceutical company AB Science is focusing on the development of two primary drug candidates, masitinib and AB8939. The company aims to bring new therapies to market for diseases with high unmet medical needs.

Masitinib is currently under investigation in multiple clinical studies across a range of indications. These include neurodegenerative disorders such as Alzheimer's disease and ALS, as well as inflammatory conditions like multiple sclerosis. The company has also explored masitinib for rare conditions related to mast cell activation syndrome.

The second compound, AB8939, is being evaluated for its potential in oncology, particularly for the treatment of acute myeloid leukemia. AB Science indicates that this compound targets rapidly dividing cancer cells, offering a potential new therapeutic approach for aggressive blood cancers.

AB Science continues to advance its research and development pipeline, driven by scientific research and clinical trial results. The company's overall objective is to provide significant therapeutic options for patients facing serious health challenges.